<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060176</url>
  </required_header>
  <id_info>
    <org_study_id>TXA Dosage Trial</org_study_id>
    <nct_id>NCT01060176</nct_id>
  </id_info>
  <brief_title>Three Dose Regimen of Tranexamic Acid in Cardiac Surgery</brief_title>
  <official_title>Three Dose Regimen of Tranexamic Acid on Blood Loss and Allogeneic Transfusions in Cardiac Surgery With Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid is thought to be a promising substitute for aprotinin when the latter has
      seceded in 2007. Yet the ideal dosage and dosing regimen of tranexamic acid in
      cardiopulmonary bypass cardiac surgery in Chinese population remains controversial. The
      current study includes patients receiving valvular replacement and coronary artery bypass
      surgery. Three dosage regimen of tranexamic acid is delivered and blood loss, transfusions
      and clinical outcomes are recorded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of exposure to allogeneic erythrocytes transfusions</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Allogeneic RBCs were transfused if the hemoglobin level was less than 6 g/dL during cardiopulmonary bypass, less than 8 g/dL postoperatively, or less than 9 g/dL for elderly people (&gt;70 years).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of allogeneic erythrocytes transfusions</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Allogeneic RBCs were transfused if the hemoglobin level was less than 6 g/dL during cardiopulmonary bypass, less than 8 g/dL postoperatively, or less than 9 g/dL for elderly people (&gt;70 years).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and volume of fresh frozen plasma transfusion</measure>
    <time_frame>Perioperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and volume of allogeneic platelet transfusion</measure>
    <time_frame>Perioperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of reexploration for hemostasis</measure>
    <time_frame>Perioperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative blood loss</measure>
    <time_frame>Postoperatively</time_frame>
    <description>Defined as total volume of chest drainage postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastography</measure>
    <time_frame>Perioperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulatory and fibrinolytic associated moleculars</measure>
    <time_frame>Perioperatively</time_frame>
    <description>FIB, FDP, FXI:C, AT-III, D-dimer and TXB2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation associated moleculars</measure>
    <time_frame>Perioperatively</time_frame>
    <description>ET-1, IL-2, IL-6, IL-8, IL-10, TNF-Î±, NE, FN and PGI2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU and hospital postoperatively</measure>
    <time_frame>Postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>High dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid with a loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid with a loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic acid with a loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>High dosage</arm_group_label>
    <arm_group_label>Low dosage</arm_group_label>
    <arm_group_label>Medium dosage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatic or recessive valvular disease patients requiring valvular replacement
             surgery with cardiopulmonary bypass

          -  Coronary artery disease patients requiring coronary artery bypass surgery with
             cardiopulmonary bypass

          -  Wrriten consent obtained

        Exclusion Criteria:

          -  Non-primary cardiac surgery

          -  Preoperative liver or renal dysfunction

          -  Preoperative coagulation disorder

          -  Allergy

          -  Pregnancy or lactation

          -  Disabled in spirit or law

          -  Fatal conditions such as tumour
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihuan Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lihuan Li, MD</last_name>
    <phone>86-10-88398184</phone>
    <email>llhfw@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Shi, MD</last_name>
    <phone>86-10-88322467</phone>
    <email>shiandypumc@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihuan Li, MD</last_name>
      <phone>86-10-88398184</phone>
      <email>llhfw@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Jia Shi, MD</last_name>
      <phone>86-10-88322467</phone>
      <email>shiandypumc@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lihuan Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jia Shi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Associate Professor and Vice Chair of the Department of Anesthesiology, Fuwai hospital, NCCD, PUMC &amp; CAMS</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>cardiac surgery procedures</keyword>
  <keyword>hemostasis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

